MedTrace Logo

A Prospective Epidemiologic Study of ALK-Positive NSCLC in China

NCT02042105 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3649

Last updated 2017-03-01

No results posted yet for this study

Summary

This is a post-marketing, observational, non-interventional, multi-central study of patients with non-small cell lung cancer (NSCLC), with data collected prospectively from medical records at inclusion. The primary objective is to obtain the epidemiologic data of anaplastic lymphoma kinase (ALK)-positive in unselected Chinese patients with NSCLC.

Conditions

  • Non-small-cell Lung Cancer

Sponsors & Collaborators

  • Guangdong Association of Clinical Trials

    lead OTHER

Principal Investigators

  • Yi-Long Wu, MD · Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences

  • Yi-Long Wu, MD · Guangdong Provincial People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-11
Primary Completion
2015-04-15
Completion
2016-07-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02042105 on ClinicalTrials.gov